RxDoctor Payments Data

Ray Johnson, MD

Interventional Cardiology · Augusta, GANPI 1124046545

Payments from drug & device makers

$1,314in general payments, 2019–2025

Across 67 payments — averaging $19.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$233
  • Pfizer$192
  • E.r. Squibb & Sons, L.L.C.$176
  • Johnson & Johnson$150
  • Inari Medical, Inc.$109
  • Philips North America LLC$86
  • plus $368 from 12 others

What the payments were for

  • Food & beverage$1,314100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,314 in reported general payments places this provider in the 5th percentile of 218 interventional cardiology providers in Georgia.

See all interventional cardiology providers in Georgia

Medicare billing

Part B allowed, 2024
$72,336
Medicare patients
1,078
Services billed
1,748

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban113$112,872
Repatha SureclickEvolocumab22$21,950
XareltoRivaroxaban23$16,851
EntrestoSacubitril/Valsartan20$15,327
Potassium Chloride104$1,336
Metoprolol Succinate140$1,239
Flecainide Acetate39$1,213
Losartan Potassium54$812
Atorvastatin Calcium118$710
Diltiazem 24hr Er (Cd)Diltiazem Hcl35$695
Amiodarone Hcl16$678
Carvedilol74$622
Rosuvastatin Calcium26$525
Warfarin Sodium47$506
Digoxin18$487

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$192$112,872113 claims
Johnson & JohnsonXarelto$150$16,85123 claims
NovartisEntresto$58$15,32720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 5th percentile of 218 interventional cardiology providers in Georgia.

Other interventional cardiology in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →